Madrigal Pharmaceuticals, Inc. (MDGL) News
Filter MDGL News Items
MDGL News Results
|Loading, please wait...|
MDGL News Highlights
- For MDGL, its 30 day story count is now at 3.
- Over the past 17 days, the trend for MDGL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ICPT, BODY and DRUG are the most mentioned tickers in articles about MDGL.
Latest MDGL News From Around the Web
Below are the latest news stories about MADRIGAL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal...
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
Now may be the time to scoop up high-quality names that continue to trade at very favorable valuations.
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trialA supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint resultsThese data will be presented at the NASH-TAG Conference on Friday January 6th, 2023 CONSHOHOCKEN, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage
Chemomab's (CMMB) phase II study evaluating CM-101 in NASH patients met its primary endpoint of safety and tolerability.
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023.
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results.
This week was going down as one to remember for Madrigal Pharmaceuticals (NASDAQ: MDGL). According to data compiled by S&P Global Market Intelligence, the biotech's shares were an eye-watering 350% higher week to date, as of Thursday's market close. Biotechs tend to pop like that when they report excellent clinical-trial results; such was the case with Madrigal.
These drug stocks to buy look poised to generate huge profits for investors., both in 2023 and in subsequent years.